Evolving Paradigms in Recurrent/Metastatic SCCHN

Introduction

Program Overview

NCCN Recommendations for a MDT for Patients With SCCHN

Role of MDT in Optimal Patient Management

MDT Management of SCCHN: All Voices Heard

Case: Initial Presentation (January 2015)

Case: Imaging at Presentation (January 2015)

Case: Investigations (January 2015)

Case: Diagnosis and Initial Treatment

Case Continuation: November 2015

Imaging: November 2015

Treatment: November 2015

Imaging: April 2016

Head and Neck Cancer: Prognostic Factors

Metastatic SCCHN: Watch and Wait Approach

Metastatic/Recurrent SCCHN: Treatment Considerations

NCCN Guidelines: Very Advanced Head and Neck Cancer

Platinum-Based Chemotherapy Plus Cetuximab*: EXTREME Trial

TPEx as First-Line Tx in Recurrent/Metastatic SCCHN: A Phase 2 GORTEC Study

Case Continuation: Treatment (April 2016)

Imaging: Treatment Response (December 2016)

Case Continuation: Disease Progression (February 2017)

Imaging: February 2017

Metastatic/Recurrent SCCHN: Treatment Considerations (cont)

Common Disease Progression in Metastatic/Recurrent SCCHN

Role of Immunotherapy in Metastatic/Recurrent SCCHN

Nivolumab for Recurrent SCCHN*: CheckMate 141

Efficacy and Safety of Pembrolizumab in Recurrent/Metastatic SCCHN Efficacy and Safety of Pembrolizumab in Recurrent/Metastatic SCCHN*: KEYNOTE-012, a Phase 1b Study

KEYNOTE-040: Pembrolizumab vs Standard Treatment in Recurrent/Metastatic SCCHN

Data Sets Supporting the Use of Immunotherapy in Patients With Recurrent/Metastatic SCCHN

Recurrent/Metastatic SCCHN: Use of Single-Agent Chemotherapy

Clinical Trial Enrollment in Recurrent/Metastatic SCCHN

First-Line Use of Anti-PD-1 Immunotherapy for SCCHN

Anti-PD-1 Immunotherapy: AE Profile

Platinum-Based Chemotherapy Plus Cetuximab: Managing AEs

Immune-Related AEs Induced by Anti-PD-1 Immunotherapy

Case Continuation: Second-Line Treatment

Combination Immune-Oncology Agents in SCCHN

Conclusions

Abbreviations